Shorter combo shows promise for tough melanoma
NCT ID NCT03149029
First seen Dec 08, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This study tested a combination of three drugs—pembrolizumab (Keytruda), trametinib (Mekinist), and dabrafenib (Tafinlar)—in 16 people with advanced melanoma that could not be removed by surgery. The goal was to see if a shorter course of targeted therapy plus immunotherapy could control the cancer for at least 6 months. The approach aims to reduce treatment side effects while still keeping the disease in check.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts general Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.